Acceptability and feasibility of plasma phosphorylated‐tau181 in two memory services

Abstract

AbstractBackgroundPlasma phosphorylated‐tau181 (p‐tau181) represents a novel blood‐based biomarker of Alzheimer's disease pathology. We explored clinicians' experience of the utility of plasma p‐tau181 in Camden and Islington Memory Services.MethodsPatients were identified by their clinician as appropriate for p‐tau181. Their p‐tau181 result was plotted on a reference range graph provided to clinicians. This was discussed with the patient at diagnostic feedback appointment.ResultsTwenty‐nine participants' plasma p‐tau181 samples were included (mean age 74 SD 8.5, 65% female). Nine clinicians participated in the study. Eighty‐six percent of clinicians found the p‐tau181 result to be helpful and in 93% of cases it was clearly understandable. The p‐tau181 result was useful in making the diagnosis in 44% of cases.ConclusionsPlasma p‐tau181 is a feasible test for use in memory services and acceptable to clinicians. Clinician feedback on utility in dementia diagnoses was mixed. Further work is required to provide education and training in understanding and interpreting ambiguity in biomarker results.